Drug intelligence / Profile preview

GNUV101

Development stage: Preclinical
Lead developer: Genuv
Modality: Small Molecules

Overview

GNUV101 is a small molecule inhibitor of MEK1 and MEK2 (MEK1/2) being developed by Genuv Inc. for the treatment of neurodegenerative diseases. Unlike repurposed MEK inhibitors, GNUV101 is a new chemical entity designed to leverage the role of the MEK/ERK signaling pathway in neural stem cell differentiation. The drug's mechanism of action involves promoting neurogenesis and providing neuroprotection by inducing the differentiation of neural stem cells into functional neurons and protecting existing neurons from damage. As of recent reports, the compound is in the preclinical stage of development, with Genuv exploring its potential across various neurodegenerative conditions.

Targets

MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)

Beyond the preview

Go deeper on GNUV101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GNUV101.

Explore the full profile